Halozyme Therapeutics, Inc. (HALO)
68.94
+1.50
(+2.22%)
USD |
NASDAQ |
May 19, 15:30
Halozyme Therapeutics Research and Development Expense (Quarterly) : 25.56M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 961.60M |
| Agenus, Inc. | 11.82M |
| Inovio Pharmaceuticals, Inc. | 13.75M |
| Curis, Inc. | 6.449M |
| LadRx Corp. | 0.0288M |